Biomunex Pharmaceuticals is a Paris- and Cambridge-based biopharmaceutical company developing innovative immunotherapies to address unmet medical needs in oncology. The company leverages its proprietary BiXAb® platform, next-generation technologies enabling the rapid and cost-effective generation of bi- and multi-specific antibodies from any pair of monoclonals.

BiXAb® has been validated through strategic collaborations with Ipsen with a major licensing agreement worth up to $610M, but also with Sanofi and Onward Therapeutics.

Biomunex is pioneering MAIT engagers, a novel class of bispecific antibodies designed to mobilize MAIT cells to selectively eliminate tumor cells, and destroy solid tumors. This approach has the potential to improve safety and efficacy compared to existing T cell engagers.

With a strong pipeline, including clinical-stage assets, Biomunex aims to advance disruptive therapies while establishing strategic partnerships and securing additional funding to accelerate development.